Home > News > 55/Prognosis of incidental left bundle branch block
Arrhythmia
Read Time: < 1 min

55/Prognosis of incidental left bundle branch block

Published Online: October 4th 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr55
Authors: A Zegard (Presenting Author) – Aston University, Birmingham, UK; O Okafor – Aston University, Birmingham, UK; J DeBono – Queen Elizabeth Hospital, Birmingham, UK; R Steeds – Queen Elizabeth Hospital, Birmingham, UK; L Hudsmith – Queen Elizabeth Hospital, Birmingham, UK; B Stegemann – Medtronic Inc, Maastricht, The Netherlands; A Jani – Queen Elizabeth Hospital, Birmingham, UK; H Marshall – Queen Elizabeth Hospital, Birmingham, UK; B Holloway – Queen Elizabeth Hospital, Birmingham, UK; Qiu – Aston University, Birmingham, UK; F Leyva – Aston University, Birmingham, UK
Quick Links:
Article
Article Information
Article:

Background: Incidental LBBB (iLBBB) is a frequent cause for cardiology referrals. In such instances, there may be uncertainty as to its prognosis and need for clinical follow-up. Cardiovascular magnetic resonance (CMR) is the gold-standard for myocardial phenotyping.

Objectives: To determine the utility of CMR in the risk stratification of patients with iLBBB.

Methods: CMR was used to identify the myocardial phenotype of patients with iLBBB. We compared outcomes of patients with an iLBBB with (iLBBBCMR+) or without (iLBBBCMR–) an abnormal CMR scan with healthy controls as well as age- and sex-matched individuals in the general population (life tables).

Results: In patients with iLBBB (n=199, aged 62.9 ± 12.6 years (mean ± SD), CMR was abnormal in 136 (68.4%) and was attributed to ischaemic (30 [15.1%]), non-ischaemic (94 [47.2%]) causes, hypertension (24 [12.1%]) and aortic valve disease (7 [3.5%]). Over 4 (2.5–5.3) years (median [interquartile range]), iLBBBCMR+ had a higher risk of total mortality or major adverse cardiac events (adjusted hazard ratio [aHR]: 8.48, 95% confidence interval [C.I.] 2.56–28.1, p<0.001), total mortality (aHR: 4.96, 95% C.I. 1.44–17.1, p=0.011) and total mortality or heart failure hospitalisation (aHR: 7.75, 95% C.I. 2.31–26.0, p=0.001) compared with controls. iLBBBCMR- had a similar risk of all endpoints. iLBBBCMR- patients had a similar survival to controls and the general population.

Conclusions: Over two thirds of patients with a iLBBB had an abnormal myocardial phenotype on CMR. Outcomes in iLBBBCMR+ were poor. Survival in iLBBBCMR- was comparable to the general population.

 

Article Information:

Further Resources

Share this Article
Related Content In Arrhythmia
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72